Facebook Pixel Addressing Women's Health with Portable Devices | BioSpectrum Asia - business - Magzter.comでこの記事を読む
Magzter GOLDで無制限に

Magzter GOLDで無制限に

10,000以上の雑誌、新聞、プレミアム記事に無制限にアクセスできます。

$149.99
 
$74.99/年

試す - 無料

Addressing Women's Health with Portable Devices

BioSpectrum Asia

|

BioSpectrum Asia June 2025

The confluence of innovation, affordability, and accessibility creates a compelling market proposition for healthcare providers, diagnostic chains, corporate wellness programmes, and public health systems alike in cancer care with focus on women's cancer in Asia.

Addressing Women's Health with Portable Devices

Cancer continues to be one of the leading causes of death worldwide, and in Asia, where nearly half of the world’s population resides, the burden is particularly profound. Among women, breast and cervical cancer are among the most prevalent, yet also the most preventable when detected early. However, vast disparities in healthcare infrastructure, especially in lowand middle-income countries, often delay diagnosis and treatment. It is here that accurate and affordable cancer screening, enabled by portable medical devices, offers transformative potential. This is a critical health issue and also a strategic growth opportunity.

Addressing a Critical Need in Women’s Health

Asia presents a diverse and complex healthcare landscape. In countries like India, Indonesia, and the Philippines, rural populations still face challenges in accessing even basic diagnostic services. The prevalence of late-stage detection in these regions is high, and survival rates are correspondingly low. For breast and cervical cancers, which can be effectively managed if detected early, the lack of early screening is a major contributor to mortality.

Portable screening devices are uniquely suited to address this challenge. Compact, easy-to-use, and powered by battery or mobile technologies, these tools can be deployed outside of traditional hospital settings. From urban clinics to rural health camps, they bring early detection capability to the point of need. In the case of breast cancer, technologies like iBreastExam, a non-invasive, radiation-free device, allow community health workers to perform standardised breast exams without the need for expensive imaging infrastructure. Similarly, portable colposcopes and HPV test kits are changing the game for cervical cancer screening.

BioSpectrum Asia からのその他のストーリー

BioSpectrum Asia

BioSpectrum Asia

India–EU FTA Paves Way for Expanded Healthcare Trade

On January 27, 2026, after years of negotiations, India and the European Union announced a landmark Free Trade Agreement.

time to read

4 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

PreferCo and Glatt to open CoE for precision fermentation bioprocess scale-up in India

In a major boost to Government of India's BioE3 push, German major Glatt and India-based startup PreferCo have announced the launch of \"PreferCo-Glatt Centre of Excellence (CoE) for Bioprocess Scale-Up\" in Hyderabad's Genome Valley.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Women's Health Surge in APAC

The rising burden of diseases such as ovarian cancer, breast cancer, cervical cancer, infertility, etc. is emerging as the key driver of the women's healthcare market across the globe. While North America led the women healthcare market in 2025, Asia Pacific (APAC) is expected to witness the fastest growth this year onwards. As a result, governments across the APAC region, are recognising the importance of women's health and are launching initiatives, particularly under female leaders, to improve access to healthcare services. Moreover, a number of women-led startups are now developing new solutions to address this growing burden of women-associated diseases in the APAC region. Let's take a closer look.

time to read

6 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Hanchor Bio receives US FDA Orphan Drug Designation for HCB101 in gastric cancer

Taiwan-based biotech startup HanchorBio, Inc. has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Daiichi Sankyo names Dr John Tsai as Global Head of R&D

Japan-based Daiichi Sankyo Company has appointed Dr John Tsai to succeed Dr Ken Takeshita, who is stepping down as Global Head of R&D, effective April 1, 2026.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

"The global trend is moving beyond centralised hubs toward distributed networks and domestic capability"

King Faisal Specialist Hospital & Research Centre (KFSHRC) and US-based Germfree Laboratories have announced a strategic partnership to develop Saudi Arabia's first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus.

time to read

4 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

SEOUL'S RISKY DRUG PRICING RESET

Drug pricing has once again moved to the centre of policy debate in South Korea, with the government recently stepping back from its proposed generic drug pricing reform.

time to read

2 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Takeda and Iambic sign $1.7 B deal to advance AI driven design of small molecules

Iambic, a US-based clinical-stage life science and technology company developing novel medicines using its artificial intelligence (AI)-driven discovery and development platform, has announced a multi-year technology and discovery collaboration agreement with Japan-based Takeda Pharma that will use Iambic's industry leading AI drug discovery models to advance a select set of high-priority small molecule programmes, initially in Takeda's Oncology and Gastrointestinal and Inflammation therapeutic areas.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

S.Biomedics announces partnership with Catalent to develop and manufacture TED-A9

US-based Catalent and South Korea-based S.Biomedics have announced a strategic partnership to support the development and manufacturing of TED-A9, S.Biomedics' allogeneic pluripotent stem-cell-derived ventral midbrain-specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson's disease.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

China revises drug administration regulations to spur innovation

China has revised regulations concerning drug administration in a bid to promote drug innovation, strengthen management of online sales of medicines and reinforce drug safety supervision.

time to read

1 min

BioSpectrum Asia March 2026

Listen

Translate

Share

-
+

Change font size